Benjamin Brauzer died at the age of 68 on January 3, 2003. Ben is survived by his wife Mari and two children Emily and Josh and grandchildren. Ben was a graduate of the University of Miami School of Medicine. He completed his internship at the Harbor General Hospital in Los Angeles and returned to Miami to complete his residency in Psychiatry at the University of Miami/Jackson Memorial Medical Center. Upon completion of his Residency training, Ben joined the faculty of the Department of Psychiatry at the University of Miami. It was during Ben's first year as a faculty member that he became interested in psychopharmacology, an interest he pursued until his retirement. During Ben's early years in psychopharmacology, he was very involved in several of the studies, which were pivotal in the development of neuroleptic drugs. He was a key member of the team that was the first to evaluate the efficacy of haloperidol in the treatment of acute schizophrenia (NIMH Haloperidol/Perphenazine Study 1965–1970). Ben was Co-Principal Investigator in other important early studies evaluating long acting neuroleptic drugs in outpatients as well as many of the early clinical trial of psychotropic agents. Ben was admired and respected by his colleagues, students, and friends. His boundless enthusiasm was always tempered by good judgment and respect for others. Ben's dedication to his work and family were unwavering, yet he found time to be active in the community and the professional organizations he treasured, to name but a few ACNP, ACP, and the APA. Ben held offices both locally and nationally in the American Psychiatric Association as well as many community organizations. Ben Brauzer was a role model not only for his students and colleagues but also for all of those who had the good fortune to have known him.